# Optimal Dosage of Ticagrelor in Korean Patients With AMI

> **NCT05210595** · PHASE4 · UNKNOWN · sponsor: **Dong-A University** · enrollment: 120 (estimated)

## Conditions studied

- Acute Myocardial Infarction
- Ticagrelor

## Interventions

- **DRUG:** Clopidogrel 75 mg
- **DRUG:** Ticagrelor 60mg
- **DRUG:** Ticagrelor 45 mg

## Key facts

- **NCT ID:** NCT05210595
- **Lead sponsor:** Dong-A University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210595, "Optimal Dosage of Ticagrelor in Korean Patients With AMI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05210595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*